The present invention relates to a urea-substituted aromatic ring-linked dioxinoquinazoline and a urea-substituted aromatic ring-linked dioxinoquinoline of Formula (I), or a pharmaceutically acceptable salt thereof or a hydrate thereof. Also provided are the preparation of the compound as shown in Formula (I) and the pharmaceutically acceptable salt thereof and the use thereof as a drug. The drug is used as an inhibitor of tyrosine kinases (e.g., VEGFR-2, C-RAF, B-RAF) for treating tyrosine kinase-related diseases.
本发明涉及一种
脲取代的芳环连二噁
喹唑啉和一种
脲取代的芳环连二噁
喹唑啉的式(I),或其药学上可接受的盐或其
水合物。还提供了式 (I) 所示化合物及其药学上可接受的盐的制备方法及其作为药物的用途。该药物用作
酪氨酸激酶(如V
EGFR-2、C-RAF、B-RAF)的
抑制剂,用于治疗
酪氨酸激酶相关疾病。